Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 7, 2006

AC Immune and Genentech Ink Alzheimer’s Research Agreement Worth Up to $300M

  • AC Immune and Genentech will work together to develop anti-beta-amyloid antibodies for Alzheimer’s and other human diseases, under an exclusive global license agreement and research collaboration . AC Immune has developed conformation-specific antibodies against beta-amyloid generated by its SupraAntigen™ technology.

    Under the terms of this agreement, Genentech will provide funding for a multiyear collaborative research program and will cover all development and clinical costs of the lead antibody and subsequent antibody candidates. Genentech will make an upfront payment with the potential for a total of over $300 million in payments upon successful completion of clinical and regulatory milestones. Upon commercialization of a product, Genentech will pay AC Immune royalties on net sales of AC Immune’s antibodies.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »